Top Markets
Coin of the day
NervGen Pharma Corp. NervGen Pharma Corp.

NervGen Pharma Corp.

NGEN
Classement en actions #16729
NervGen Pharma Corp., along with its affiliated entities, is a pharmaceutical... NervGen Pharma Corp., along with its affiliated entities, is a pharmaceutical company dedicated to discovering, advancing, and commercializing innovative drug therapies for neurological conditions involving nerve damage. Its flagship investigational therapy, NVG-291, is currently undergoing Phase 1 clinical trials, targeting significant neurological disorders such as spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. NervGen has also secured an exclusive licensing agreement with Case Western Reserve University. This partnership enables the company to research, advance, and commercialize a proprietary technology holding considerable therapeutic promise for SCI and a range of other nerve-related ailments. Established in 2017, NervGen Pharma Corp. maintains its headquarters in Vancouver, Canada.
Prix de l'action
$3.78
Dernière synchronisation: 2026-03-17
Capitalisation boursière
$276.54M
Changement (1 jour)
0.00%
Changement (1 an)
45.53%
Pays
CA
Échange NervGen Pharma Corp. (NGEN)

Catégorie

EPS pour NervGen Pharma Corp. (NGEN)
EPS au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de NervGen Pharma Corp., l’EPS actuel de la société (TTM) est de 0. À la fin de 2026, la société avait un EPS de 0 égal à celui de 2026, qui était de 0.
Historique de l'EPS de NervGen Pharma Corp. de 2026 à 2026
EPS à la fin de chaque année
Année EPS Changez
Pas assez de données pour les dates fournies.
EPS pour des entreprises ou concurrents similaires
Entreprise EPS Différence d’EPS Pays
$17.32 -
US
$27.74 -
NL
$-7.98 -
US
$-5.29 -
AU
- -
CH